BP‑1‑102 exerts an antitumor effect on the AGS human gastric cancer cell line through modulating the STAT3 and MAPK signaling pathways

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Signal transducer and activator of transcription 3 (STAT3) is implicated in various cancers.
• The role of STAT3 inhibition in gastric cancer (GC) requires further investigation.
• BP-1-102 is a novel STAT3 inhibitor with demonstrated antitumor effects in other malignancies.

Purpose of the Study:

• To investigate the efficacy of BP-1-102 in human gastric cancer (GC) cell lines.
• To elucidate the molecular mechanisms underlying BP-1-102's effects in GC.
• To assess BP-1-102's impact on GC cell proliferation, apoptosis, migration, and invasion.

Main Methods:

• Treatment of human GC cell lines (AGS and HGC-27) with BP-1-102.
• Cell proliferation assays.
• Flow cytometry for apoptosis and cell cycle analysis.
• Western blot analysis to assess STAT3 phosphorylation and target gene expression.
• Evaluation of mitogen-activated protein kinase (MAPK) pathway activation.

Main Results:

• BP-1-102 dose-dependently inhibited proliferation in AGS cells but had minimal effect on HGC-27 cells.
• BP-1-102 induced apoptosis and suppressed migration and invasion in GC cells.
• BP-1-102 inhibited STAT3 phosphorylation and its downstream targets (c-Myc, cyclin D1, survivin).
• BP-1-102 modulated MAPK signaling, inducing c-Jun N-terminal kinase and p38, while inhibiting extracellular signal-regulated kinases.

Conclusions:

• BP-1-102 demonstrates significant antitumor activity in specific human gastric cancer cell lines.
• The mechanism involves the inhibition of the STAT3 signaling pathway.
• Modulation of MAPK pathways contributes to BP-1-102's anti-gastric cancer effects.
• BP-1-102 represents a potential therapeutic agent for gastric cancer.